ML 18 Chemical Properties

Boiling point:

821.8±65.0 °C(Predicted)

Density 

1.291±0.06 g/cm3(Predicted)

storage temp. 

2-8°C

solubility 

DMSO: soluble

form 

A solid

pka

11.99±0.46(Predicted)

ML 18 Usage And Synthesis

Description

ML-18 is a non-peptide bombesin receptor subtype 3 (BB₃) antagonist that inhibits [¹²⁵I]BA1 binding to NCI-H1299 lung cancer cells transfected with human BB₃ receptors (IC₅₀ = 4.8 μM). It is selective for BB₃ over the gastrin releasing peptide receptor (GRPR) and the neuromedin B receptor (NMBR) with IC₅₀ values of 16 and >100 μM, respectively, in a radioligand binding assay. ML-18 (16 μM) reversibly inhibits BA1-induced increases in cytosolic calcium in NCI-H1299 cells. It also inhibits BA1-induced phosphorylation of ERK and EGFR and reduces proliferation of NCI-H1299 cells.

Uses

ML-18 is a non-peptide bombesin receptor subtype-3 antagonist. It also inhibits lung cancer growth.

ML 18(1422269-30-4)Related Product Information

• ML346
• 5-[(4-Nitrobenzoyl)oxy]-2-[(2-pyrimidinylthio)methyl]-4H-pyran-4-one
• ML-228
• ML188 (Racemate)
• ML-098
• ML277
• ML 204
• ML329
• ML364
• VU0456810
• ML188
• ML418
• [4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone
• ML213
• N-(3,4-difluorophenyl)-2-pyridin-4-ylquinazolin-4-amine
• ML-327
• PTP1B-IN-2
• ML264